Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.01% | -11.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.01% | -11.40% | |||
| Cost of Revenue | -11.45% | 9.02% | |||
| Gross Profit | 25.19% | -21.75% | |||
| SG&A Expenses | -3.13% | -0.40% | |||
| Depreciation & Amortization | 0.16% | -26.32% | |||
| Other Operating Expenses | 181.66% | -192.36% | |||
| Total Operating Expenses | 3.40% | -11.65% | |||
| Operating Income | 62.91% | -9.27% | |||
| Income Before Tax | 135.30% | -427.91% | |||
| Income Tax Expenses | 156.37% | -377.31% | |||
| Earnings from Continuing Operations | 130.35% | -442.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 4.48% | 36.37% | |||
| Net Income | 130.32% | -442.98% | |||
| EBIT | 62.91% | -9.27% | |||
| EBITDA | 86.25% | -41.88% | |||
| EPS Basic | 130.33% | -442.68% | |||
| Normalized Basic EPS | 123.70% | -39.64% | |||
| EPS Diluted | 129.86% | -448.48% | |||
| Normalized Diluted EPS | 120.25% | -38.63% | |||
| Average Basic Shares Outstanding | 0.00% | 0.08% | |||
| Average Diluted Shares Outstanding | 1.56% | -1.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 56.62% | -1.02% | |||